Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: New insight into the biology of Schnitzler syndrome

Haematologica

Volumn 97, Issue 11, 2012, Pages 1699-1703

  Terpos, Evangelos ^a   Asli, Bouchra ^b,c   Christoulas, Dimitrios ^a   Brouet, Jean Claude ^b,c   Kastritis, Efstathios ^a   Rybojad, Michel ^b   Bengoufa, Djaouida ^b   Dimopoulos, Meletios A ^a   Fermand, Jean Paul ^b,c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

Angiogenesis; Bone formation; Schnitzler syndrome; VEGF

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANGIOGENIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; CARBOXY TERMINAL TELOPEPTIDE; CORTICOSTEROID; DICKKOPF 1 PROTEIN; IMMUNOGLOBULIN M; OSTEOCALCIN; OSTEOPROTEGERIN; PEFLOXACIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE REMODELING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; OSSIFICATION; RASH; SCHNITZLER SYNDROME; TREATMENT RESPONSE; URTICARIA; WALDENSTROEM MACROGLOBULINEMIA; X RAY;

ADULT; AGED; ANGIOGENIC PROTEINS; ANTIGENS, DIFFERENTIATION; BONE RESORPTION; FEMALE; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; OSTEOGENESIS; SCHNITZLER SYNDROME; URTICARIA;

EID: 84868568168     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.067306     Document Type: Article

References (24)

1. Lipsker D, Veran Y, Grunenberger F, Cribier B, Heid E, Grosshans E. The Schnitzler syndrome. Four new cases and review of the literature. Medicine (Baltimore). 2001;80(1): 37-44.
2. de Koning HD, Bodar EJ, van der Meer JW, Simon A; Schnitzler Syndrome Study Group. Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin Arthritis Rheum. 2007;37(3): 137-48.
3. Asli B, Brouet JC, Fermand JP. Spontaneous remission of Schnitzler syndrome. Ann Allergy Asthma Immunol. 2011;107(1):87-8.
4. van Deuren M, Kroot JJ, Swinkels DW. Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist. Haematologica. 2009;94(9):1297-300.
5. Migliorini P, Del Corso I, Tommasi C, Boraschi D. Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease? Eur Cytokine Netw. 2009;20(3):108-11.
6. Gran JT, Midtvedt Ø, Haug S, Aukrust P. Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature. Scand J Rheumatol. 2011;40(1):74-9.
7. Ramadan KM, Eswedi HA, El-Agnaf MR. Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab. Br J Dermatol. 2007;156(5):1072-4.
8. Bozeman S, Lewis S. Schnitzler syndrome successfully treated with methotrexate. Ann Allergy Asthma Immunol. 2008;101 (2):219.
9. Dinarello CA. Blocking IL-1 in systemic inflammation. J Exp Med. 2005;201(9): 1355-9.
10. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res. 2002;8(7):2210-6.
11. Kastritis E, Terpos E, Anagnostopoulos A, Xilouri I, Dimopoulos MA. Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. Clin Lymphoma Myeloma. 2006;7(1):73-6.
12. Terpos E, Anargyrou K, Katodritou E, Kastritis E, Papatheodorou A, Christoulas D, et al. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int J Cancer. 2012;130 (3):735-42.
13. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor kappaB ligandosteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102(3):1064-9.
14. Terpos E, Fragiadaki K, Konsta M, Bratengeier C, Papatheodorou A, Sfikakis PP. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29(6):921-5.
15. Asli B, Bienvenu B, Cordoliani F, Brouet JC, Uzunhan Y, Arnulf B, et al. Chronic urticaria and monoclonal IgM gammopathy (Schnitzler syndrome): report of 11 cases treated with pefloxacin. Arch Dermatol. 2007;143(8):1046-50.
16. D'Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011;118(17):4663-5.
17. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, Tsionos K, Bamias A, et al. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. Br J Haematol. 2007;137(6):560-8.
18. Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M, et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol. 2009;183(7):4705-14.
19. Terpos E, Anagnostopoulos A, Kastritis E, Bamias A, Tsionos K, Dimopoulos MA. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemia. Br J Haematol. 2006; 133(3):301-4.
20. Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y. IL-1 plays an important role in the bone metabolism under physiological conditions. Int Immunol. 2010;22(10):805-16.
21. Liu XH, Kirschenbaum A, Yao S, Levine AC. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system. Endocrinology. 2005;146(4):1991-8.
22. Stashenko P, Obernesser MS, Dewhirst FE. Effect of immune cytokines on bone. Immunol Invest. 1989;18(1-4):239-49.
23. Samee M, Kasugai S, Kondo H, Ohya K, Shimokawa H, Kuroda S. Bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) transfection to human periosteal cells enhances osteoblast differentiation and bone formation. J Pharmacol Sci. 2008;108(1):18-31.
24. Zhang C, Dai H, de Crombrugghe B. Characterization of Dkk1 gene regulation by the osteoblast-specific transcription factor Osx. Biochem Biophys Res Commun. 2012;420(4):782-6.